Bio Roundup: CAR-T & Migraine Races, Intra-Cellular, Rockefeller & More
Xconomy
SEPTEMBER 30, 2016
—Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen. TheStreet.com has more here. Phase 3 trials should start next year.
Let's personalize your content